Navigation Links
Curemark Begins Autism Trials at Two More Sites
Date:6/1/2010

RYE, N.Y., June 1 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago.  A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.

CM-AT is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  CM-AT has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.

"Curemark's clinical trial program is making rapid progress, with enrollment moving forward quickly at our CM-AT trial sites," said Dr. Joan Fallon, Curemark founder and CEO.  "We're also considering additional sites with potential interest in participating in the CM-AT clinical research."  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
2. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
3. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
4. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
5. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
6. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
7. Curemark Announces Senior Executive Promotions
8. Curemark CEO Presents at Epigenomics Conference
9. Curemark Closes Series A Financing
10. Curemark Appoints Preeminent Pediatrics Gastroenterologist
11. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  "Blood Tests replace ... announced ....." The Diagnostic, Monitoring and Screening ... cancer diagnostics is occurring using in vitro blood ... company with impressive backing, has announced a single ... is moving faster than the market. New technology ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & ... The diabetes and obesity disease cluster is currently dominated ... and type 2 diabetes mellitus (T2DM), and the majority ... quality of products, is attributable to these indications. While ... large market presence, there are a large number of ...
(Date:12/6/2016)... 2016 Anaplastic Oligoastrocytoma - Pipeline Review, ... latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic ... overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... forms when two types of cells in the ... number to form a mass. These brain cells ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood associated ... appearing online in the journal Radiology. , Heart disease and brain disease exact a ... the rapidly aging population. Damage to both organs often occurs at a subclinical stage, ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart Agencies, ... South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing ... a brain tumor. , Jason Bauer and his family are longtime members of ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are ... children are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas ... bring to the children of the world. , In exchange for generous donations, customers ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... proud to announce that its fully redesigned website, which launched October 17, 2016, ... a sleek responsive design and easy-to-navigate layout. Visitors and patients can discover the ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live From program ... Marketing Awards competition. Live From won in the Use of Social Media category. ... successful projects undertaken by the media industry’s most innovative marketing professionals. ...
Breaking Medicine News(10 mins):